Literature DB >> 10795741

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

B Salomon1, D J Lenschow, L Rhee, N Ashourian, B Singh, A Sharpe, J A Bluestone.   

Abstract

CD28/B7 costimulation has been implicated in the induction and progression of autoimmune diseases. Experimentally induced models of autoimmunity have been shown to be prevented or reduced in intensity in mice rendered deficient for CD28 costimulation. In sharp contrast, spontaneous diabetes is exacerbated in both B7-1/B7-2-deficient and CD28-deficient NOD mice. These mice present a profound decrease of the immunoregulatory CD4+CD25+ T cells, which control diabetes in prediabetic NOD mice. These cells are absent from both CD28KO and B7-1/B7-2KO mice, and the transfer of this regulatory T cell subset from control NOD animals into CD28-deficient animals can delay/prevent diabetes. The results suggest that the CD28/ B7 costimulatory pathway is essential for the development and homeostasis of regulatory T cells that control spontaneous autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10795741     DOI: 10.1016/s1074-7613(00)80195-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  667 in total

Review 1.  How the immune system works to protect the host from infection: a personal view.

Authors:  C A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

2.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 3.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 4.  Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy.

Authors:  Irene Athanassakis; S Vassiliadis
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

5.  Antigen-induced regulation of T-cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors.

Authors:  Sten-Erik Bergström; Mehmet Uzunel; Toomas Talme; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

6.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

8.  The Critical Role of TGF-beta1 in the Development of Induced Foxp3+ Regulatory T Cells.

Authors:  Song Guo Zheng
Journal:  Int J Clin Exp Med       Date:  2008-06-10

Review 9.  TSLP in epithelial cell and dendritic cell cross talk.

Authors:  Yong-Jun Liu
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

10.  Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues.

Authors:  Kristin Melli; Rachel S Friedman; Ashley E Martin; Erik B Finger; Gang Miao; Gregory L Szot; Matthew F Krummel; Qizhi Tang
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.